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Purpose: Few studies have addressed the specific behavioral changes associated with pri-
mary brain tumor (PBT). This paper will report on the frequency and demographic/clinical
correlates of such behaviors, and the reliability of rating such behaviors among people with
PBT, family informants, and clinicians. The association of behavioral changes and patient
functional status will also be discussed.
Methods: A total of 57 patients with 37 family informants were recruited from two large
Australian metropolitan hospitals. Each completed three neuro-behavioral self-report mea-
sures; the Emotional and Social Dysfunction Questionnaire, the Frontal Systems Behavior
Scale, and the Overt Behavior Scale. Patients also completed a depression symptom
measure. Functional status was defined by clinician-rated Karnofsky performance status.
Results: Patients were on average 52 years old, a median of 4 months (range 1–82) post-
diagnosis, with high grade (39%), low grade (22%), or benign tumors (39%). Patients
reported frequency rates of 7–40% across various behavioral domains including anger,
inappropriate behavior, apathy, inertia, and executive impairment. The presence of epilep-
tic seizures was associated with significantly higher levels of behavioral changes. Notably,
behavior did not correlate with tumor grade or treatment modality. There was moder-
ate agreement between patients and relatives on the presence or absence of behavioral
changes, and substantial agreement between relative and clinician ratings. Depressed
patients did not generally report more changes than non-depressed patients. Increases in
the relative and clinician-rated behavior scores were significantly correlated with decreasing
functional status in the patient.
Conclusion: Behavioral changes were a common sequela of both benign and malignant
PBT. Larger scale studies are required to confirm these results. The results suggest the
importance of including behavior in brain cancer psychosocial assessments and the need
to develop interventions to treat these patients and reduce the burden of care on families.
Keywords: brain tumor, behavioral change, challenging behaviors, executive dysfunction, awareness,
functional status
INTRODUCTION
There are a range of well-known neurological, cognitive, and psy-
chological effects that can manifest in adults with primary brain
tumor (PBT). These occur as a result of direct tumor infiltra-
tion, associated treatment-related effects, and also dealing with,
as in the case high-grade glioma, the psychological impact of
a disease with such a poor prognosis. Neurologic symptoms (1,
2), impairments of cognition (3–5), and changes in mood (6–8)
have been documented across high, low, and benign tumor grades.
However, the frequency and correlates of behavioral changes that
adults with PBT may experience have received limited attention.
In contrast, a diverse range of behavioral changes have been doc-
umented across other neurologic diseases and injuries including
stroke, Alzheimer’s disease, and traumatic brain injury (9–11), as
well as among children with PBTs (12).
Neurologically-mediated behavioral changes can span dysreg-
ulated behavior, executive elements of cognitive function and
diminished motivation/initiation (e.g., apathy) (10, 13). Various
regions of the frontal lobes play a major but not exclusive role
in these behavioral/cognitive processes. Behaviors such as social
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disinhibition, physical and verbal aggression, limited insight, and
loss of social judgment may be associated with lesions to the
orbitofrontal and ventromedial prefrontal cortex (10, 13–15).
Behaviors including apathy, adynamia, and perseveration can be
associated with damage to the medial prefrontal cortex and its con-
nections (10, 13, 16). Finally, lesions in the anterior cingulate and
dorsolateral prefrontal circuit may be associated with disorders
in the executive components of cognitive functioning, which also
have a role in overseeing or monitoring behavior (10, 13, 15, 17). In
addition to the local effects of neoplasms in the prefrontal cortex,
the remote effects of tumors located in other cortical and sub-
cortical regions of the brain may also affect behavioral/cognitive
functioning (18).
To date, the data on behavioral changes associated with PBT is
fragmented and limited. Research focusing on malignant tumor
patients specifically has described neuropsychiatric symptoms
including agitation, irritability, apathy, and hallucinations (5, 19).
Single-case reports (20) and first-hand accounts of relatives doc-
umented in qualitative studies (21–23) have also been published,
reporting aggression, personality change, and erratic emotional
behavior among patients with low- and high-grade malignant
tumors. A handful of group studies have reported rates of behav-
ior change between 16% (24) and 62% (25) among patients with
oligodendrogliomas (24), primary and metastatic brain tumors
(25), and survivors of acromegaly (25). However, these results need
to be viewed with some caution due to retrospective study designs
(24, 25); a lack of standardized criteria used to define behavior (24,
25), or the use of psychopathology and personality measures not
validated for a population with neurological impairment (26).
In the first study to prospectively document behavioral changes
employing a standardized measure validated for use in a neu-
rologically impaired population, rates of apathy (46%), disinhi-
bition (58%), and executive dysfunction (62%) were reported
by 26 patients with frontal low-grade tumors (27). One other
study that employed a standardized neuro-behavioral measure did
not report frequency data (28). There therefore remains a need
to further systematically and prospectively document behavioral
changes among PBT patients across all tumor grades, employing
standardized measures validated for neurologic populations.
In addition to understanding how widespread such problems
may be among the PBT population, the causes of behavioral
changes require investigation. Proposed mechanisms that have
been advanced to account for the presence of cognitive impair-
ments among people with PBT have included the tumor itself (all
grades), the site of the tumor, tumor progression, tumor-related
neurological complications, the presence of epilepsy, and side-
effects from cancer treatments (3, 5). It is not known whether
the same types of mechanisms are also associated with changed
behavior after PBT.
Seeking to quantify changes to behavior after PBT poses both
methodological and clinical challenges. Since behavior occurs
within a dynamic social context, it is difficult to assess by objec-
tive measures in a standardized setting (i.e., the test room) in
the same way as cognitive abilities are evaluated (3). Further-
more, clinicians are rarely able to directly observe all the behaviors
of concern. Consequently, clinicians typically gather information
about behavior through patient self-report using interviews or
validated neuro-behavioral measures (29). However, the presence
of memory impairments or a lack of insight may limit the reliabil-
ity of patient self-report. This problem can be offset by gathering
additional information from family members (30). Relatives and
carers are often able to contribute valuable complementary infor-
mation to provide a more complete clinical picture of a patient,and
may do so via proxy ratings on standardized measures. Therefore,
an examination of the level of concordance between clinical assess-
ment and both patient self-report and proxy (relative) ratings of
behavioral change after PBT may help to inform the development
of valid assessment approaches (27).
Finally, the possible association between changed behavior and
functional status needs testing. Poorer performance on cognitive
measures has been associated with lower levels of functional status
(4) and a similar pattern may be present with behavioral change.
Therefore, this study aimed to (i) investigate the frequency of
behavioral changes after PBT across tumor grades; (ii) examine
the demographic and clinical correlates of such behaviors; (iii)
investigate the concordance of clinical assessment with patient
and proxy reports of behavioral changes; and (iv) examine the
association of behavioral changes with functional status.
MATERIALS AND METHODS
SETTING/PARTICIPANTS
Ethical approval to undertake the study was provided by the rel-
evant New South Wales Area Health Service Human Research
Ethics Committees. Over a 12-month period (from October 2007),
all active cases of the neuro-oncology service at Liverpool Hos-
pital and the neurosurgical service at Royal North Shore Hos-
pital in Sydney, NSW, Australia, were reviewed to prospectively
recruit patients who met the study criteria. Informed consent
was obtained from all participants, with capacity to consent
determined by treating clinicians.
Patients were considered for inclusion at any stage along the
continuum of care (from recently confirmed diagnosis to palliative
care) and irrespective of treatment modality received. Inclusion
criteria for patients were (i) histologically confirmed PBT of any
grade or histology; (ii) aged ≥18 years at time of diagnosis; and
(iii) cognitively able to complete the measures. Recruited patients
were invited to nominate a relative who might also participate.
Family members needed to be first degree relatives who were
also ≥18 years old at the time of the study. Exclusion criteria for
patients and relatives were an inability to speak English and/or the
presence of severe psychiatric or substance abuse issues, as defined
by the treating healthcare team.
MEASURES
Three paper-and-pencil neuro-behavioral rating measures were
employed (see Table 1). The measures were selected on the fol-
lowing basis: (i) the validation samples for the three measures
had included people with PBT; (ii) self-rating and proxy report
versions were available, and (iii) all had good psychometric proper-
ties. One measure [the overt behavior scale (OBS) (31)] could also
be clinician-administered. Higher scores indicated higher levels of
the target problem on all three measures. “Caseness” on each of
the measures refers to behaviors that are clinically significant (i.e.,
require further assessment or intervention). More details about
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Table 1 | Description of three neuro-behavioral measure subscales
(patient versions), sample reliability coefficients (n=54), and
subscale content descriptors.
Measure Subscale Cronbach α
Frontal
Systems
Behavioral
Rating Scalea
Disinhibition (15 items)
Impulsive, childish, breaks rules, silly 0.71
Apathy (14 items)
Neglect personal appearance, does
nothing, lost interest in activities
0.72
Executive dysfunction (17 items)
Disorganized, forgetful, does not learn
from mistakes
0.81
Emotional and
Social
Dysfunction
Questionnaireb
Anger (7 items)
Easily annoyed, irritable 0.89
Emotional dyscontrol (8 items)
Excess or wrong emotional displays 0.92
Helplessness (9 items)
Scared or worried, without hope 0.90
Inertia (3 items)
Requiring prompts, lack of interest in
activities
0.71
Fatigue (4 items)
Tired, requires more sleep 0.70
Indifference (8 items)
Lacks sensitivity, does not care 0.77
Inappropriate (6 items)
Causes embarrassment, over excitable 0.60
Euphoria (6 items)
Disregard for wellbeing, relationship
difficulties, denies problems
0.65
Overt Behavior
Scalec
Verbal aggression (4 levels)
Shouts at others, makes threats –
Physical aggression (combined 3
subscales with 4 levels)
Aggression versus objects, Aggression
versus self, Aggression versus others
–
Inappropriate sexual behavior (6 levels)
Lewd talk, inappropriate touch, coercive
sexual behavior
–
Perseveration (3 levels)
Repetitious questioning, picks at skin until
injured
–
Wandering/absconding (6 levels)
Wander into others rooms, gets lost,
escapes secure area
–
Inappropriate social behavior (5 levels)
Socially awkward, nuisance, oppositional,
danger to self/others
–
Adynamia (1 level)
Needs prompting daily or multiple times
daily
–
aFrSBe patient and proxy versions employ same subscales and items.
bESDQ – patient version subscales displayed in table. Six of the eight relative
subscales have same titles as patient version, but some items are different:
anger=8 items, emotional dyscontrol=6 items, helplessness=8 items, indiffer-
ence=7 items, inappropriate=6 items, fatigue=4 items. Relative version has
two scales that are not part of the patient self-report version: maladaptive=9
items, insight=4 items.
cOvert Behavior Scale-patient, proxy and clinician versions use same levels.
the measures and descriptors of the subscale content are displayed
in Table 1.
Emotional and Social Dysfunction Questionnaire
The Emotional and Social Dysfunction Questionnaire (ESDQ)
(32) is a measure of emotional and social dysfunction developed
among neurosurgical patients with central nervous system disor-
ders. Items are grouped into eight subscales (see Table 1), each
producing a subscale score. Respondents rate all items on a 10-cm
visual analog scale (anchors “no problem” and “big problems”).
Scale scores for the self-report and relative informant versions
have been shown to discriminate between a central nervous sys-
tem group and a control group of non-central nervous system
neurosurgical patients/relative informants (24). Caseness on the
ESDQ for each subscale represents scores 2 SD above the control
group mean (32).
Frontal Systems Behavior Scale
The Frontal Systems Behavior Scale (FrSBe) (33) is a 46-item
behavior rating instrument that measures impairments across
behavioral and cognitive domains of executive impairment. Items
are grouped into three subscales (apathy, disinhibition, and execu-
tive dysfunction). Respondents rate the items on two response sets
(before the injury/illness; after the injury/illness) using a 5 point
Likert-type scale (1= almost never, to 5= almost always) and the
three raw subscale scores can be converted into standardized T -
scores (M = 50, SD= 10). The patient and proxy versions of the
FrSBe use the same items. FrSBe caseness represents scores 1.5 SD
or more (i.e., T -score of 65 or greater) above results derived from
a normative sample (33).
The Overt Behavior Scale
The OBS (31) is an instrument that measures nine categories
of challenging behaviors among brain-injured populations (see
Table 1). Within each category, all behavioral levels are scored as
simply present (1) or absent (0) (severity score). An accompanying
scale weights the levels to reflect the variation in clinical severity
among behaviors (e.g., on the inappropriate sexual behavior scale,
sexual assault is more serious than lewd comments), producing
the clinically weighted severity score (range 0–77). The OBS can
be completed by clinicians and relatives (using the same levels)
and also has a patient self-report version. The OBS global caseness
represents the presence of the most severe behaviors in each of the
nine categories.
A data protocol was devised to collect information on demo-
graphic, clinical, and psychosocial variables (see Table 2). A
clinician-rated Karnofsky performance status (KPS) (34) was also
collected. The KPS is a classification scale widely used in the neuro-
oncology field. Clinicians rate patients into an ascending series
of categories ranging from full functionality (KPS score= 100)
through to death (KPS score= 0).
DATA COLLECTION
Patients with PBT who met the study criteria were mailed an infor-
mation letter and were followed up with a phone call to ascertain
if they wished to participate. After providing informed consent,
patients completed the measures in a face-to-face interview con-
ducted by the study research staff at the hospital’s outpatient
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Table 2 | Sociodemographic and clinical characteristics (n=54).
Variable n (%) or Mdn (range)
Age (years) 53 (19–91)a
Months post-diagnosis 4 (1–81)
Sex
Male 24 (44)
Female 30 (56)
Years of education 12 (6–16)
Histological diagnosis
Astrocytoma Grade 1–2 6 (11.1)
Astrocytoma Grade 3 4 (7.4)
Glioblastoma grade 4 16 (29.6)
Oligodendroglioma/oligoastrocytoma Grade 2–3 4 (7.4)
Meningioma 15 (27.8)
Otherb 9 (16.7)
Tumor grade/type
High-grade glioma 21 (38.9)
Low-grade glioma 12 (22.2)
Benign PBT 21 (38.9)
Tumor site
Frontal/temporal 29 (53.7)
Other 25 (46.3)
Tumor lateralization
Left-side 24 (44.4)
Right-side 22 (40.8)
Both 8 (14.8)
Treatment stagec
Post-surgery 3 (5.6)
Active treatment (RT, chemotherapy) 15 (27.8)
Post-treatment 35 (64.8)
Palliative 1 (1.9)
Neurosurgical intervention
Biopsy 12 (22.2)
Resection (sub or gross total) 42 (77.8)
Radiation therapy
Yes 32 (59.3)
No 22 (40.7)
Chemotherapy
Temozolomide 16 (29.6)
Other 1 (1.9)
None 37 (68.5)
Radiation (RT) dose
5040–6000 cGy 30 (55.6)
<5040 cGy 2 (3.5)
None 22 (40.7)
Epileptic seizures
Yes 25 (46.3)
No 29 (53.7)
Corticosteroids (current use)
Yes 10 (18.5)
No 36 (66.7)
Unknown 8 (14.8)
(Continued)
Variable n (%) or Mdn (range)
Karnofsky performance status 80 (50–100)
100–90 19 (35.2)
80 23 (42.6)
70–50 12 (22.2)
aFor analysis of age and time post-diagnosis variables, group divided by median
split ≥53 versus <53 years, and ≥4 versus <4 months, respectively.
bOther: craniopharyngioma n=2, epidermoid tumor n=1, ependymoma Grade
2 n=2, medulloblastoma n=1, pituitary adenoma n=2, schwannoma n=1.
cPost-treatment=disease monitoring phase with no active tumor treatment regi-
men, Palliative=no further active treatment indicated other than supportive care.
clinics or at the respondent’s home. Patients and relative infor-
mants independently completed the measures during the same
appointment. The patients tolerated the test battery, which took
between 30 and 60 min to administer. Only one patient was discon-
tinued due to an inability to comprehend items on the measures.
No patient discontinued the battery due to fatigue or cognitive
overload. Some respondents completed the measures by hand,
others through oral administration. Interviewing clinicians rated
the respondent on the OBS and KPS. Patient’s clinical informa-
tion for the data protocol was extracted from hospital medical
files, which included reports from neuroimaging investigations,
clinical history taking, and clinical examination (see Table 2 for
range of variables).
DATA ANALYSIS
Data were entered into SPSS version 17.0. Descriptive statistics
were generated for all variables. Inspection for normality found
that only two variables (ESDQ subscale scores) from the mea-
sures had non-normal distributions using the criterion specified
by Tabachnick and Fidell (35). Following Andrewes et al. (32), a
square root transformation was performed on the two subscale
scores (ESDQ patient version: emotional dyscontrol, hopeless-
ness). The subscales then met the criterion for normality, enabling
the use of parametric statistics for subsequent analyses.
To report on the frequency rates (Aim i), dichotomous vari-
ables recording caseness (yes versus no) were generated for the
ESDQ, FrSBe, and OBS variables (see Table 3). To examine the
relationship between demographic or clinical variables and the
12 behavioral variables (OBS clinical weighted score, the 3 FrSBe,
and 8 ESDQ self-rated subscale scores) (see Table 3), a series of
t -tests and three-factor analyses of variance were conducted (Aim
ii). Independent variables comprised sex, age, treatment timing
(time post-diagnosis, treatment phase), tumor grade, tumor site
and lateralization, tumor stage, treatment modality (neurosurgical
intervention, radiation therapy, radiation dose, and chemother-
apy), epileptic seizures, and use of corticosteroids (see Table 2).
The significance level was adjusted using a Bonferroni correction
(0.05/12, α= 0.004) in order to control for Type 1 error due to
multiple comparisons.
To examine the reliability of the behavioral reports (Aim
iii), two approaches were taken. Internal consistency for the
patient reports on the FrSBe and ESDQ subscales was tested
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Table 3 | Mean scores and frequency of behavioral changes (n=54).
Variables Patients (n=54)
M (SD) n (%) caseness
FrSBea
Apathy 59.2 (14.3) 19 (35.2)
Disinhibition 52.5 (11.6) 9 (16.7)
Executive impairments 60.8 (15.1) 22 (40.7)
ESDQ
Anger 2.5 (2.0) 11 (20.4)
Emotional dyscontrol 1.5 (1.9) 4 (7.4)
Helplessness 1.9 (1.9) 4 (7.4)
Inertia 2.3 (2.1) 18 (33.3)
Fatigue 3.1 (2.2) 11 (20.4)
Indifference 1.6 (1.3) 5 (9.3)
Inappropriate behavior 1.2 (1.0) 12 (22.2)
Euphoria 1.5 (1.2) 4 (7.4)
OBS: category severity score
Verbal aggression – 15 (27.8)
Physical aggression – 9 (16.7)
Inappropriate sexual behavior – 0 (0.0)
Perseveration – 8 (14.8)
Wandering/absconding – 2 (3.7)
Inappropriate social behavior – 3 (5.6)
Initiation problems – 14 (25.9)
Global caseness – 17 (45.9)
Clinical weighted severity 1.9 (3.1) –
aT-scores.
FrSBe, frontal systems behavior scale; ESDQ, emotional and social dysfunction
questionnaire; OBS, overt behavior scale.
Table used with permission, Cancer Institute of NSW.
using Cronbach’s α (36). The coefficients were interpreted fol-
lowing the recommendations by Streiner (37) (<0.8= excellent;
0.7–0.8= adequate; 0.6–0.7= questionable; >0.6 poor). Second,
comparison of agreement between clinicians, family, and patient
self-report was possible for the subset of patients (n= 37) with
participating family members. Kappa (κ) statistics were calcu-
lated to ascertain the level of agreement between clinician ratings
and both patient self-report and proxy (family) ratings, based on
responses to a specifically created OBS global “caseness” vari-
able (any behavioral change present versus absent). Following
Landis and Koch (38), a κ statistic of 0.21–0.40 was interpreted
as representing fair agreement, 0.41–0.60 moderate agreement,
and 0.61–0.80 substantial agreement. Using the same OBS global
caseness variable, frequencies of false positives and false nega-
tives in identifying behavioral changes were calculated (clinician
assessment versus patient self-report). Analyses (t -tests) were also
carried out to test for any between-group differences (patients
versus carers) in the patient versus carer ratings on the FrSBe,
ESDQ, and OBS clinical weighted severity variable scores. Finally,
Pearson product-moment correlation was employed to exam-
ine the association between behavior variable scores and the
KPS (Aim iv).
RESULTS
SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS
A total of 154 patients with PBT from Liverpool and Royal
North Shore hospital were reviewed, with 85 patients meeting the
inclusion criteria. Exclusion reasons were too unwell/cognitively
impaired (n= 41), non-English speaking (n= 5), presence of
severe psychiatric problems (n= 4), and not contactable (n= 21).
A total of 57 out of the 85 (a 67% response rate) agreed to take
part and completed the study protocol. Three patients from the
57 were identified as outliers for time post-diagnosis (>10 years
post-diagnosis) by means of the visual inspection of a histogram
and were therefore excluded, leaving a final sample of 54 partici-
pants. The demographic and clinical variables for the sample are
reported in Table 2.
From the sample of 54 patients, 45 family members were identi-
fied. No family member could be identified for seven participants,
and two were from non-English speaking families. The sample
were a mean age of 48.1 years (SD= 16.2), predominantly female
(n= 25, 68%), with an average of 12.0 years (SD= 3.2) educa-
tion. Most family respondents were the spouses of the patient
with PBT (n= 26, 70.3%), with smaller numbers of adult children
(n= 5, 13.5%), parents (n= 4, 10.8%), and siblings (n= 2, 5.4%)
participating. Eight family members declined to take part in the
study (39).
FREQUENCY OF BEHAVIORAL DISTURBANCE
Rates of patient (n= 54) self-reported behavior that reached
“caseness” levels varied from a high of 40% (executive impair-
ment) to 7% (emotional dyscontrol, helplessness, euphoria) (see
Table 3). Clinically significant levels of apathy, inertia, anger, and
inappropriate behavior were reported at rates between 20 and 35%.
Family members (n= 37) rated behaviors that met the case-
ness criteria ranging from 60% (apathy) to 8% (Euphoria) (see
Table 4). Clinically significant behavioral changes were also
observed for disinhibition, executive impairment, anger, indiffer-
ence, fatigue, and initiation problems, with rates ranging from
22 to 36%. Patients (n= 37) and families (n= 37) also provided
pre-diagnosis ratings on the three FrSBe subscales. Comparing
the pre-diagnosis and current scores (paired t -tests), significant
increases in apathy (pre-diagnosis mean 49.5± 14.0, p= 0.001)
and executive impairment (pre-diagnosis M = 51.9, SD= 13.6,
p= 0.001) were reported by patients but not disinhibition (pre-
diagnosis M = 51.9, SD= 13.6, p= 0.10). Families also reported
significant increases in apathy (pre-diagnosisM = 56.7,SD= 18.0,
p= 0.001) and executive impairment (pre-diagnosis M = 51.9,
SD= 13.6, p= 0.001) with a trend for disinhibition at p< 0.01
(pre-diagnosis M = 52.4, SD= 15.6, p= 0.08). The behavioral
changes reported by patients and family members were indicative
of disorders of activation and executive dysfunction (10, 13).
DEMOGRAPHIC AND CLINICAL CORRELATES OF BEHAVIORAL
CHANGES (N = 54)
Only one clinical variable, epileptic seizures, demonstrated a pat-
tern of association with the behavioral variables. With Bonfer-
roni correction, patients experiencing epileptic seizures reported
significantly higher levels of Inertia (on ESDQ, p= 0.002) and
challenging behaviors (clinical weighted OBS score, p= 0.003).
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Table 4 | Mean scores and frequency of behavioral changes (n=37).
Variables Patients (n=37) Carers (n=37)b Clinicians (n=37)
M (SD) n (%) caseness M (SD) n (%) caseness M (SD) n (%) caseness
FrSBea
Apathy 61.2 (13.6) 15 (40.5) 69.4 (18.5) 22 (59.5) – –
Disinhibition 52.3 (10.9) 7 (18.9) 55.6 (16.4) 10 (27.0) – –
Executive impairments 63.1 (13.0) 19 (51.4) 61.8 (17.2) 13 (35.1) – –
ESDQ
Anger 2.8 (2.1) 10 (27.0) 2.8 (2.0) 11 (30.6) – –
Emotional dyscontrol 1.6 (1.9) 3 (8.1) 1.4 (2.1) 6 (16.7) – –
Helplessness 2.1 (1.9) 3 (8.1) 2.0 (2.1) 6 (16.7) – –
Fatigue 3.3 (2.3) 6 (16.2) 3.3 (2.3) 9 (25.0) – –
Indifference 1.8 (1.3) 5 (13.5) 1.9 (2.2) 13 (36.1) – –
Inappropriate behavior 1.3 (1.0) 10 (27.0) 0.9 (1.2) 3 (8.3) – –
OBS: category severity score
Verbal aggression – 10 (27.0) – 10 (27.0) – 3 (8.1)
Physical aggression – 6 (16.2) – 7 (18.9) – 3 (8.1)
Inappropriate sexual behavior – 0 (0.0) – 0 (0.0) – 0 (0.0)
Perseveration – 5 (13.5) – 6 (16.2) – 9 (24.3)
Wandering/absconding – 1 (2.7) – 2 (5.4) – 0 (0.0)
Inappropriate social behavior – 2 (5.4) – 4 (10.8) – 8 (21.6)
Initiation problems – 8 (21.6) – 8 (21.6) – 9 (24.3)
Global caseness – 17 (45.9) – 20 (54.1) – 15 (40.5)
Clinical weighted severity 1.8 (3.4) – 1.9 (2.7) – 1.4 (2.1) –
aT-scores.
bCarers n=36, missing data= 1.
FrSBe, frontal systems behavior scale; ESDQ, emotional and social dysfunction questionnaire; OBS, overt behavior scale.
Table used with permission, Cancer Institute of NSW.
In addition, several other subscale scores were higher in the
seizure group at the p= 0.05 (FrSBe: apathy, disinhibition, and
executive dysfunction; ESDQ: anger, helplessness, and fatigue).
No similar pattern of significant association with behavioral
change was observed among the other demographic and clinical
variables.
The distribution of patients reporting epileptic seizures
(yes versus no) across tumor grade (high, low, benign) was
then examined. The overall chi-square statistic was significant
(χ2= 6.6, p= 0.036), with the raw data indicating that signifi-
cantly higher numbers of patients reported seizures among the
low-grade tumors. Apart from epileptic seizures, patients with a
frontal/temporal tumor were more likely to report a higher score
on the ESDQ indifference subscale. This was the only other sig-
nificant association. There were no differences related to age, time
post-diagnosis, sex, education, tumor grade, tumor lateralization,
or treatment (phase, neurosurgery, radiation, chemotherapy, or
current use of corticosteroids).
RELIABILITY IN RATING BEHAVIORAL CHANGES
The internal consistency coefficients were found to range from
adequate to excellent (Cronbach’s α> 0.7) for all ESDQ and FrSBe
self-report subscales, with the exception of inappropriate behavior
and euphoria (see Table 1). These results indicated that patients
with PBT were able to respond consistently to the questionnaire
items, rather than in an inconsistent or random way. Kappa val-
ues for the level of clinician-patient agreement on the presence
versus absence of behavioral change was significant (κ= 0.45,
p< 0.006) but represented moderate agreement only. The agree-
ment between clinician and relative ratings was stronger (κ= 0.63,
p< 0.000), representing a substantial level of agreement. In 10.8%
(4/37) of cases, clinicians identified the presence of a behavioral
change, which was not identified by the patient. In 16.2% (6/37)
of cases, patients reported the presence of a behavioral change not
classified as present by the clinician. Finally, there were no sig-
nificant between-group differences among carers versus patients
(n= 37) comparing the median scores on the FrSBE, ESDQ, or
OBS-clinically weighted severity scores (t -tests).
FUNCTIONAL STATUS AS A CORRELATE OF BEHAVIORAL CHANGE
Pearson product-moment correlations were employed to examine
the relationship among patient, relative and clinician behavioral
ratings (n= 37), and the KPS. Significant negative correlations
were present between the KPS and relative ratings (p= 0.01)
for the FrSBe apathy r =−0.48, FrSBe executive dysfunction
r =−0.47, and the ESDQ fatigue r =−0.46 scores. Three variables
were also correlated to the KPS at p= 0.05 level (ESDQ helpless-
ness r =−0.38, inappropriate r =−0.37, insight r =−0.39). The
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clinician-rated score on the OBS also showed a strong negative
correlation with the KPS (OBS clinical weighted score r =−0.55,
p= 0.01). No significant correlations were found between patient
self-reported behavior and the KPS.
DISCUSSION
This study has systematically documented the frequency of behav-
ioral changes after PBT, drawing upon patient self-report, family,
and clinician perspectives. Rates of behavioral changes were wide-
spread in the current study, with 7–60% present at clinically
significant levels based on patient and family informant reports.
Notably, the behavioral changes were observed across high-grade
glioma, low-grade glioma, and benign brain tumors. If this finding
is supported by further larger scale studies, it will have implica-
tions for psychosocial care, because a wide range of families will
need support to manage such changes (39).
Although the presence of dysregulated behaviors after PBT have
been documented in case studies and qualitative reports, to the
best of our knowledge this is only the second study to have sys-
tematically and prospectively investigated this issue. At the global
level, the rates of disinhibition in the current sample were lower
than those reported by Gregg and colleagues (27), and this may
reflect differences in the tumor profiles between the two samples
(i.e., in Gregg’s study, half the sample were recruited on the basis
of having focal frontal tumors). Looking at more specific types of
dysregulated behavior, elevated levels of irritability or anger have
been reported (8), and anger including the more severe presenta-
tion of verbal and physical aggression were found at levels around
30%, as rated both by patients and family carers.
Disorders of activation such as apathy have been investigated
more frequently in previous studies and the current report rein-
forces such findings (3–5, 27). The rates in this study were in a
similar range to those reported by Gregg and colleagues (ranging
between 40 and 60%) (27). The next step will be to test the extent
to which disorders of activation or dysregulation are independent
of, or can be accounted for, by the presence of depression, also
commonly observed after PBT.
The current study also documented the prevalence of executive
cognitive impairments, but once again at rates lower than those
reported by Gregg et al. (27). The findings from a behavioral rating
scale such as the FrSBe assists in providing more comprehensive
data about such impairments in everyday life, supplementing data
from objective neuropsychological tests. The behavioral rating
scales address concerns about the ecological validity of standard-
ized cognitive tests in predicting “real world” performance due
to the lack of novelty and unpredictability in the structured test
environment, for which people need to draw upon their execu-
tive cognitive systems (40). Overall, the frequency of behavioral
change is a further reminder of the vulnerability of all regions of
the prefrontal cortex and their connections to the effects of PBT.
There is evidently a complex interplay between the direct effects
of the tumor location and infiltration (4), compounded by the
potential effects of surgical resection, radiotherapy (41), and/or
chemotherapy. In addition, concomitant medications including
anti-convulsants (42, 43), may contribute to the pathophysiolog-
ical alterations that can manifest as behavioral changes across all
tumor grades.
Patient self-report showed a moderate agreement with clini-
cian assessment of the presence of behavior changes. This provides
support to previous findings that many people with PBT still have
sufficient intact cognitive reserves to reliably report on their own
behavior to some degree (44). In contrast, Gregg et al. (27) found
that patients with frontal tumors reported significantly higher lev-
els of disinhibition than patients with non-frontal tumors. In the
current study, despite the level of patient–clinician agreement,
there was stronger, substantial agreement between proxy (fam-
ily) reports and clinician ratings. These findings are consistent
with other studies, which have investigated levels of agreement
in identification of symptoms among patients with other neuro-
logic conditions (e.g., dementia), treating clinicians, and family
members (30). Finally, the current study did not find signifi-
cant differences in reporting of behavioral/executive impairments
between carers and patients on the FrSBe, similar to the earlier
study by Gregg et al. (27).
The strong correlation between the presence of epileptic
seizures and behavioral change has not been previously docu-
mented after PBT, but has been found among children in the
general population with seizures [e.g., Ref. (45)]. Epileptic seizures
have been identified as a risk factor for a mix of cognitive and
behavioral impairments in adults with PBT and the current results
may reflect similar underlying mechanisms (3, 5, 27, 46). The sig-
nificant number of seizures in the low-grade glioma group in the
current study is consistent with the broader literature, which has
reported high rates of epilepsy among patients with low-grade
tumors (43, 47–49). Some anti-epileptic medications, particularly
Levetiracetam, can be a confounding variable; however, as behav-
ioral disturbances are a known side effect. Only two patients in
the current sample were on Levetiracetam at the time of the study
recruitment, and thus the effect of such a medication could not
account for the elevated levels of behavioral change reported across
the sample.
The nature of the association between behavioral changes and
the KPS remains to be elucidated. The behaviors may be an expres-
sion of frustration arising from the experience of living with
lower functional status. Equally possible, the presence of disrup-
tive and challenging behaviors may lead to decreasing social and
occupational engagement, which is then reflected in the declin-
ing functional rating. Alternatively, lowered functional status and
increased behavior change may both be accounted for by another
variable, such as the worsening of the tumor.
The study has a number of limitations. A total of 41 patients
were too unwell or cognitively impaired to participate in the study.
Therefore, the current frequency rates may be conservative, as few
patients experiencing progressive or recurrent disease in the pal-
liative phase of management participated in the study, particularly
in the high-grade subgroup. This remains an ongoing method-
ological challenge when studying this patient cohort, as this group
may well include a significant number of patients with behavioral
changes. Furthermore, it is likely that different mechanisms con-
tribute to the presence of behavioral change across the different
tumor grades (e.g., epilepsy as a causal factor among the low-grade
tumor group) but a more detailed analysis of the possible causes
within different tumor grades was beyond the scope of this study.
Finally, the reason why eight family carers declined to participate
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in the study are not known, and therefore the impact this may have
had on the carer ratings is difficult to assess.
Larger scale studies within each tumor grade are required to
confirm these initial findings. These results require replication in
a longitudinal study in a broader population. This will help clarify
whether behavioral changes fluctuate and resolve during the recov-
ery phase after treatment, or are part of the longer-term effects
of the tumor and/or treatments. The correlation between behav-
ioral changes and cognitive functioning also needs exploration, as
well as the impact of behavioral changes on health-related quality
of life. Clinically, the study findings highlight the importance of
including questions to patients and family members about behav-
ioral changes in clinician assessments and reviews. The subsequent
challenge is to develop both appropriate screening measures and
subsequent interventions to effectively manage such issues when
they arise and to reduce the burden of care on families (6, 39).
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